Literature DB >> 18226677

Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials.

Janneke H H M van de Wijgert1, Peter H Kilmarx, Heidi E Jones, John M Karon, Supaporn Chaikummao.   

Abstract

BACKGROUND: Candidate vaginal microbicides could cause genital irritation, which in turn could facilitate HIV transmission instead of preventing it. While genital epithelial findings are documented in a standardized manner in most microbicide trials, little is known about background rates and predictors for many types of genital findings. STUDY
DESIGN: A secondary analysis was conducted using data from a Phase II expanded safety study of the candidate microbicide Carraguard gel (Population Council, NY, USA) in Thailand. Genital findings were identified by visual inspection of the cervix, vaginal walls and external genitalia during pelvic exams prior to gel use (screening and enrollment) and during gel use (at 2 weeks and Months 1-12). Women were interviewed about potential risk factors for genital findings at every visit and tested routinely for sexually transmitted and vaginal infections.
RESULTS: A total of 258 genital findings were identified in 152 woman-years of follow-up. Genital findings were positively associated with older age, increased parity, self-report of genital symptoms, positive HSV-2 serology, bacterial vaginosis by Nugent scoring and the presence of a genital finding at baseline. Furthermore, vaginal findings were positively associated with vaginal practices and yeast infections. Genital findings were negatively associated with use of hormonal contraception, inconsistently associated with frequency of sex and applicator use, and not associated with condom use.
CONCLUSIONS: Several factors that are common in women of reproductive age account for the background rate of genital epithelial findings in this population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18226677     DOI: 10.1016/j.contraception.2007.10.006

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  4 in total

1.  Influence of contraceptive choice on vaginal bacterial and fungal microflora.

Authors:  G Donders; G Bellen; D Janssens; B Van Bulck; P Hinoul; J Verguts
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-09       Impact factor: 3.267

2.  High resolution imaging of epithelial injury in the sheep cervicovaginal tract: a promising model for testing safety of candidate microbicides.

Authors:  Kathleen L Vincent; Nigel Bourne; Brent A Bell; Gracie Vargas; Alai Tan; Daniel Cowan; Lawrence R Stanberry; Susan L Rosenthal; Massoud Motamedi
Journal:  Sex Transm Dis       Date:  2009-05       Impact factor: 2.830

3.  In vitro inhibition of human papillomavirus following use of a carrageenan-containing vaginal gel.

Authors:  Akiva P Novetsky; Marla J Keller; Ana Gradissimo; Zigui Chen; Stephanie L Morgan; Xiaonan Xue; Howard D Strickler; José A Fernández-Romero; Robert Burk; Mark H Einstein
Journal:  Gynecol Oncol       Date:  2016-09-10       Impact factor: 5.482

4.  A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days.

Authors:  Craig R Cohen; Joelle Brown; Anna-Barbara Moscicki; Elizabeth A Bukusi; Jeremy R A Paull; Clare F Price; Stephen Shiboski
Journal:  PLoS One       Date:  2011-01-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.